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Chordomas are rare, slow-growing but clinically aggressive tumors predominantly found in the sacrum, spine, and clivus.19 They are thought to 
be derived from vestiges of the notochord, a mesoderm-
derived structure that is involved in the process of neuru-
lation and embryonic development.7,16,21 Chordomas com-
pose approximately 1%–4% of all primary bone tumors10 
with an age-adjusted incidence rate in the general popula-
tion of 0.8 per 1 million people.13,19 Their locally destruc-
tive behavior precludes gross-total resection in 50% of 
cases, contributing to its dismal prognosis with 5-, 10-, 
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Object. Chordoma cells can generate solid-like tumors in xenograft models that express some molecular char-
acteristics of the parent tumor, including positivity for brachyury and cytokeratins. However, there is a dearth of 
molecular markers that relate to chordoma tumor growth, as well as the cell lines needed to advance treatment. The 
objective in this study was to isolate a novel primary chordoma cell source and analyze the characteristics of tumor 
growth in a mouse xenograft model for comparison with the established U-CH1 and U-CH2b cell lines.
Methods. Primary cells from a sacral chordoma, called “DVC-4,” were cultured alongside U-CH1 and U-CH2b 
cells for more than 20 passages and characterized for expression of CD24 and brachyury. While brachyury is believed 
essential for driving tumor formation, CD24 is associated with healthy nucleus pulposus cells. Each cell type was 
subcutaneously implanted in NOD/SCID/IL2Rgnull mice. The percentage of solid tumors formed, time to maximum 
tumor size, and immunostaining scores for CD24 and brachyury (intensity scores of 0–3, heterogeneity scores of 0–1) 
were reported and evaluated to test differences across groups.
Results. The DVC-4 cells retained chordoma-like morphology in culture and exhibited CD24 and brachyury 
expression profiles in vitro that were similar to those for U-CH1 and U-CH2b. Both U-CH1 and DVC-4 cells grew 
tumors at rates that were faster than those for U-CH2b cells. Gross tumor developed at nearly every site (95%) in-
jected with U-CH1 and at most sites (75%) injected with DVC-4. In contrast, U-CH2b cells produced grossly visible 
tumors in less than 50% of injected sites. Brachyury staining was similar among tumors derived from all 3 cell types 
and was intensely positive (scores of 2–3) in a majority of tissue sections. In contrast, differences in the pattern and 
intensity of staining for CD24 were noted among the 3 types of cell-derived tumors (p < 0.05, chi-square test), with 
evidence of intense and uniform staining in a majority of U-CH1 tumor sections (score of 3) and more than half of 
the DVC-4 tumor sections (scores of 2–3). In contrast, a majority of sections from U-CH2b cells stained modestly for 
CD24 (scores of 1–2) with a predominantly heterogeneous staining pattern.
Conclusions. This is the first report on xenografts generated from U-CH2b cells in which a low tumorigenic-
ity was discovered despite evidence of chordoma-like characteristics in vitro. For tumors derived from a primary 
chordoma cell and U-CH1 cell line, similarly intense staining for CD24 was observed, which may correspond to 
their similar potential to grow tumors. In contrast, U-CH2b tumors stained less intensely for CD24. These results 
emphasize that many markers, including CD24, may be useful in distinguishing among chordoma cell types and their 
tumorigenicity in vivo.
(http://thejns.org/doi/abs/10.3171/2014.4.SPINE13262)
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and 20-year survival rates of 67%, 40%, and 13%, re-
spectively. A major contributor to the lack of efficacious 
therapy lies in the relative paucity of knowledge about 
in vivo chordoma biology and growth characteristics.3 
Chordomas are diagnosed by their molecular presenta-
tion of S100 protein, epithelial membrane antigen, select 
cytokeratins (cytokeratin 5/8, 18, or 19), and Brachyury 
(T),14,22 a T-box transcription factor whose expression is 
limited to the notochord during development. Brachyury 
expression in adult tissue has been used as a specific and 
sensitive diagnostic aid for chordoma. Additional mark-
ers of chordoma have also been suggested, including 
elevated protein expression of alpha enolase (ENO1), 
pyruvate kinase M2 (PKM2), gp96,23 and CD24, a gly-
coprotein expressed on many B lymphocytes and mature 
granulocytes that is known to be specifically expressed 
in chordoma18 and notochordal nucleus pulposus cells.8 
How these molecular markers relate to tumor growth or 
presentation in chordoma remains poorly understood.
Only recently have investigators begun to develop 
animal models of chordoma as a means to advance un-
derstanding of chordoma biology.11,12,14,20 To date, very 
few chordoma cell lines have been reported, namely 
U-CH117 and U-CH2b,2 along with many more puta-
tive chordoma cell lines. Only a few of  these have been 
shown to generate tumors in established mouse xenograft 
models and to retain molecular characteristics of the par-
ent tumor and expanded cells. Presneau and coworkers 
used an established murine model in the NOD/SCID/
IL2Rgnull mouse to establish tumor formation using the 
human U-CH1 cell line.14 At 10 weeks after subcutaneous 
injection of U-CH1 cells in a laminin-rich Matrigel car-
rier, xenografts were generated with morphological and 
molecular profiles (that is, brachyury expression) typical 
of conventional chordomas. Subsequently, Hsu et al.11 and 
Siu et al.20 detailed an ability to generate chordoma xeno-
grafts from patient-derived primary human tumor cells 
(called “JHC7” and “JHH-2009–011,” from sacral and 
clival chordomas, respectively). A majority of the studies 
documenting successful xenograft growth from primary 
chordoma cells have used positive staining for brachyury, 
as well as cytokeratin, to confirm the existence of chor-
doma. These results have demonstrated that patient cell 
sources from primary tumor can generate solid tumors ex 
vivo that have some of the molecular characteristics and 
features of the parent tumor. However, information is still 
lacking about which molecular markers of chordoma cell 
lines and primary chordoma cells are associated with sta-
ble and successful xenograft growth of chordoma tissues.
The objective of this study was to isolate and expand 
chordoma cells from a primary tumor using modifica-
tions of methods previously developed for isolating noto-
chordal cells of the nucleus pulposus.5,6,9 This work relied 
on enzymatic digestion protocols and plating on laminin-
rich substrates to retain physaliphorous cells from the 
parent tumor that retain the CD24+ and T+ molecular 
profile of the parent tumor in cell culture and in xeno-
grafts generated in NOD/SCID/IL2Rgnull mice. Studies 
of isolated cells in culture and xenografts derived from 




Chordoma tissue (> 7 cm) was resected en bloc from 
the sacrum of a 74-year-old male patient and sent for pa-
thology review. The tumor was described as mesenchy-
mal with physaliphorous cells that were immunoreactive 
for keratins (monoclonal mouse anti–human cytokeratin, 
clones AE1/AE3 and MNF116, DakoCytomation; clone 
CAM5.2, Becton Dickinson) and epithelial membrane 
antigen and irregularly reactive for S100 protein. Tumor 
samples were collected in accordance with protocols 
approved by the Duke University Institutional Review 
Board, and written informed consent to remove and study 
the tumor tissues for research purposes was obtained from 
the patient before surgery. Tumor samples were placed in 
sealed tissue containers and stored at 4°C for less than 
4 hours prior to transportation to the laboratory. Tumor 
samples were separated into 2 sections for cell isolation 
and histological examination.
Tissue Characterization by Immunostaining
Primary tumor tissue from the patient was embedded 
in optimal cutting temperature medium, immediately flash 
frozen in liquid nitrogen, and stored at -80°C for cryosec-
tioning. Sections (7 mm) were fixed with formaldehyde (10 
minutes, room temperature) and incubated with blocking 
serum (5% goat serum and 3.75% bovine serum albumin 
[BSA], Zymed). Sections were then incubated with pri-
mary antibodies against cytokeratin 5/8 primary antibody 
(MAB3228, mouse monoclonal anti-human antibody, Mil-
lipore), brachyury (Ab20109, polyclonal anti-human anti-
body, Santa Cruz Biotechnology Inc.), or CD24 (555426, 
mouse monoclonal anti-human antibody, BD Biosciences) 
for 2 hours. Sections were then incubated with appropri-
ate secondary antibody (30 minutes, Alexa 488 goat anti-
rabbit antibody or anti-mouse antibody, Molecular Probes) 
and counterstained with propidium iodide (0.2 mg/ml, 15 
minutes, Sigma). Prior to incubation with the primary an-
tibody, sections labeled for brachyury were first permea-
bilized with 0.2% Triton for 10 minutes at room tempera-
ture. For all sections, negative controls were incubated with 
rabbit IgG for polyclonal antibody and appropriate isotype 
controls (mouse IgG1 or IgG2a) for monoclonal antibodies 
to confirm specificity of the antibody. 
Cell Isolation
For cell isolation, tumor tissues were digested using a 
sequential pronase-collagenase digestion previously devel-
oped for nucleus pulposus cells of the intervertebral disc.4 
Cells were then plated on tissue culture plastic coated with 
various proteins to best promote retention of the chordoma 
morphology, as described here. To coat surfaces for cell 
culture, T25 flasks were first incubated with 2 ml of a 0.1% 
gelatin solution (2% stock solution diluted in H2O, G1393, Sigma) for approximately 30 minutes or with 2 ml of me-
dium conditioned with 804G mouse chondrosarcoma cells1 
at 37°C. This substrate was chosen based on prior studies 
suggesting that this matrix rich in laminin-5 (LM-332) was 
able to promote attachment and retention of larger vacu-
olated cells of the immature nucleus pulposus.9 Solution 
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was then aspirated, and flasks were allowed to dry in an 
upright position at room temperature. Tumor tissues were 
first rinsed several times in wash medium (DMEM, high 
glucose, Gibco) supplemented with Fungizone (1 mg/ml, 
Gibco), kanamycin (diluted 1:100, K0129, Sigma), and 
gentamycin (0.165 mg/ml, Gibco), very lightly minced, and 
incubated 14–16 hours at 37°C in wash medium supple-
mented with 0.06% collagenase Type 2 (Worthington Bio-
chemicals) and 0.04% pronase (Roche Applied Science). 
The remaining cell suspension was spun at 400g to collect 
the cell pellet and twice washed with wash medium. Iso-
lated cells were resuspended in culture medium (4:1 ratio 
of Iscove’s modified Dulbecco’s medium [IMDM, 12440, 
Invitrogen]/RPMI 1640 [R8758, Sigma] with 10% fetal 
bovine serum [FBS, Hyclone]) supplemented with 100 U/
ml penicillin-streptomycin (14140–122, Invitrogen/Gibco) 
and plated on T25 tissue culture flasks coated with 804G 
conditioned medium as described above (0.5–1 × 106 cells 
per flask).
Cells were incubated in culture at 37°C with infre-
quent medium changes (1–2 weeks) and were passaged 
when at 75% confluence. After the first passage, a subset 
of cells were split (1:2) and cultured on gelatin-coated as 
well as 804G-coated flasks. Cells were passaged at ap-
proximately 1- to 2-week intervals until Passages 12–15, 
after which doubling times appeared to slow for some 
populations. A subset of cells on both the 804G- or gela-
tin-coated flasks continued to grow with doubling times 
of approximately 10 days for more than 1 year. These 
cells were called “DVC-4 cells” (Duke-Veterans Affairs 
Chordoma-4), as they were from the fourth chordoma tu-
mor resected for cell culture and expansion at that facil-
ity. Cells were periodically imaged or harvested for flow 
cytometry or immunohistochemical analyses.
Cell Culture
Two chordoma cell lines were acquired for com-
parative purposes through a materials transfer agreement 
with the Chordoma Foundation: human chordoma cell 
lines U-CH1 and U-CH2b (University Hospital of Ulm, 
Germany). Each cell line was separately cultured as fol-
lows.17 In brief, T75 flasks were coated with 3 ml of a 
0.1% gelatin solution as described for the cell isolation 
protocol above. The U-CH1 or U-CH2b cells were plat-
ed on flasks at 106 cells/ml and cultured in a 4:1 ratio of 
IMDM (12440, Invitrogen)/RPMI 1640 (R8757, Sigma) 
supplemented with 10% FBS and 100 U/ml penicillin-
streptomycin (15140–122, Invitrogen/Gibco).
Flow Cytometry
Primary cells obtained from culture and U-CH1 cell 
lines were periodically analyzed via flow cytometry to 
quantify expression levels of the cell surface marker CD24. 
Freshly isolated (Passage 0) and passaged cells were re-
leased from culture via trypsin and resuspended in phos-
phate-buffered saline (PBS, Gibco) at a concentration of 
106 cells/ml. Cells were then incubated for 30 minutes at 
4°C with CD24–fluorescein isothiocyanate (FITC) mouse 
monoclonal antibody (10 mg/ml, MCA1379FT, AbD Se-
rotec) or mouse IgG1-FITC negative control (MCA928F, 
AbD Serotec), washed 2 times with PBS, and analyzed on 
an Accuri C6 flow cytometer (Becton Dickinson) to mea-
sure the (geometric) mean fluorescence intensity (MFI) 
and percentage of cells positive for surface proteins (%). 
Immunoglobulin G control values were recorded and 
subtracted from experimental values of fluorescence. A 
minimum of 10,000 cells were analyzed for each condition 
(CD24, control) for each time point.
To label cells for brachyury, cells were fixed with 4% 
formaldehyde, washed with PBS containing 0.1% saponin 
(558255, EMD Millipore Chemicals Inc.), and incubated 
with a polyclonal anti–human antibody (20109, Santa 
Cruz Biotechnology Inc.). Cells were washed twice with 
PBS containing 0.1% saponin and incubated with appro-
priate secondary antibody (10 mg/ml Alexa Fluor 488 
goat anti-rabbit IgG, Molecular Probes) for 30 minutes at 
4°C. Cells were analyzed on a flow cytometer to measure 
MFI and percentage of T+ cells as described above.
Immunostaining of Cultured Cells
Primary cells in culture and U-CH1 and U-CH2b 
cell lines were periodically examined for the presence 
of brachyury, as for the native tissue. Cells were released 
from substrates with trypsin and transferred to tissue 
chamber slides for labeling and visualization. Cells were 
fixed with 4% formaldehyde (10 minutes, room tempera-
ture), permeabilized with 0.2% Triton X-100 in PBS (2 
minutes, Sigma), incubated with blocking serum (5% goat 
serum and 3.75% BSA), and incubated with primary and 
secondary antibodies, as for the tissue sections described 
above (polyclonal anti–human brachyury, Ab20109, San-
ta Cruz Biotechnology Inc.). Secondary antibody alone 
was used as a negative control.
Molecular Characterizations of Primary Cells
As the primary tumor cell isolates (DVC-4) were 
previously unstudied, the mRNA and genomic DNA for 
brachyury were evaluated as follows. Total mRNA and 
genomic DNA from DVC-4 cells (Passage 14) were iso-
lated using standard techniques. Complementary DNA 
was generated from mRNA by random priming, and 
approximately 40 ng of RNA equivalents were used for 
quantitative polymerase chain reaction (PCR; Applied 
Biosystems 7900 PCR system) using primers for brachy-
ury, CD24, and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH), as described previously.2 Genomic copy 
number was determined via multiplex quantitative PCR 
using 10 ng of genomic DNA and brachyury gene-spe-
cific primers and/or probe, with normalization for input 
DNA using commercially available telomerase reverse 
transcriptase–specific primers (4401633, Applied Biosys-
tems).22 All assays were performed in quadruplicate.
Subcutaneous Xenograft Model
For this study, we used a strain of mice previously 
shown to be supportive of chordoma xenografts,14 the NOD/
SCID/IL2Rgnull (NSG) mouse (25–30 g, Jackson Laborato-
ry). Mice (8 mice per U-CH1, U-CH2b; 2 mice per DVC-4) 
underwent sedation for subcutaneous injection of cells (1–5 
× 106 cells in 200 μl of Matrigel, Becton Dickinson) into 2 
locations per mouse: the interscapular region and a region 
overlying the right or left iliac crest. The contralateral iliac 
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crest site was used to deliver 200 μl of Matrigel alone as 
a control. Primary tumor cells (DVC-4) of Passage 2 were 
used for this procedure. Mice were returned to normal cage 
activity and monitored daily for evidence of tumor growth 
and adverse effects. All protocols were performed with ap-
proval from the Duke University Institutional Animal Care 
and Use Committee.
Gross measures of tumor size were obtained from 
photographs of each mouse to estimate a total tumor bur-
den. All mice were euthanized when the tumor burden 
exceeded approximately 2000 mm3. The parameters of 
time to euthanization and percentage of tumors formed 
per injection site were recorded for all mice. When the 
mice were euthanized, subcutaneous tumors were ex-
cised, immediately flash frozen in liquid nitrogen, and 
stored at -80°C until cryosectioning. 
Immunohistochemical Staining of Xenograft Tissue
For histological evaluation, solid tumor was prepared 
from mice representative of each xenograft model (5 
tumor samples each for U-CH1 and U-CH2b; 2 tumor 
samples for DVC-4). Frozen tissue sections (7 mm, 3 sec-
tions per tumor, with 30-mm spacing) were prepared from 
excised tumor, fixed in 4% formaldehyde (10 minutes at 
room temperature), and incubated with primary anti–hu-
man brachyury, CD24, and appropriate secondary anti-
bodies as described above. For each tumor section, the 
intensity of staining was recorded as 0 = no staining, 1 = 
diffuse and light intensity of staining (cell associated), 2 
= moderate and moderately distributed intensity of stain-
ing (cell associated), and 3 = intense and widely distrib-
uted intensity of stain. As some regions in the xenograft 
tissues were very heterogeneous with evidence of differ-
ent tissue types, we also provided a score for uniformity 
of staining: 0 = heterogeneous or nonuniform staining 
and 1 = homogeneous or uniform staining throughout the 
section. Pearson’s chi-square test was used to test for the 
significance of differences in intensity and uniformity.
Results
Histological Appearance of Primary Tumor and Isolated 
Cells
Sections of the patient tumor stained positively for cy-
tokeratin, brachyury, and CD24 (Fig. 1). The sections stud-
ied were very homogeneous in appearance and contained 
physaliphorous cells in “stringy” arrays, as described pre-
viously. Primary cells isolated from the patient tumor at-
tached to tissue culture plastic coated with either gelatin or 
the laminin-rich 804G-conditioned medium (Fig. 2). Cells 
maintained a rounded appearance on both substrates out 
to Passage 10, with many cells appearing very large in di-
ameter and containing vacuoles typical of notochordal and 
chordoma cells. These cells were slightly slower to pas-
sage, however, with initial doubling times of approximately 
10 days rather than the 7 days for U-CH1 cells. There was 
some evidence that cells began to spread out and elongate 
on the gelatin substrates, distinct from the chordoma-spe-
cific appearance.
Biomarkers of Chordoma Cells in Primary Cells and  
Tumor Cell Lines
Primary DVC-4 cells stained positively for brachyury 
immediately upon isolation. As shown in Fig. 3, brachy-
ury staining was also present in virtually all cells and was 
clearly nucleus associated at Day 2 after isolation, again 
out to Passage 10 (Fig. 3A and B). This brachyury expres-
sion pattern in primary DVC-4 cells was very similar to 
that in U-CH1 cells lines plated on gelatin as shown (Fig. 
3C). Messenger RNA expression levels of brachyury in 
DVC-4 cells were approximately 2-fold lower than those 
for U-CH1 according to quantitative PCR (0.50 ± 0.07–
fold relative to U-CH1). In contrast, mRNA expression 
levels of CD24 in DVC-4 were 1.6-fold higher than in 
U-CH1 according to quantitative PCR (1.62 ± 0.46–fold 
relative to U-CH1). The brachyury gene (T) from genom-
ic DNA of the DVC-4 tumor was not amplified compared 
with normal DNAs, as determined by quantitative PCR 
(data not shown).
Primary DVC-4 cells also positively labeled for 
CD24 immediately upon isolation. Note that CD24 ex-
pression was assayed in DVC-4 cells via flow cytometry. 
At the time of isolation, 49% of all cells labeled positively 
for CD24 (Fig. 4), suggesting enrichment with chordoma 
cells during continued culture. With successive passages, 
the percent of cells labeling positive for CD24 increased 
to more than 95% of all cells by Passage 21.
In Vivo Tumorigenicity of Primary Cells in Mouse  
Xenograft Model
In this study, mice injected subcutaneously with pri-
mary cells (DVC-4) or with U-CH1 or U-CH2b cells were 
monitored via visual inspection and tumor dimensional 
Fig. 1. Patient tumor tissue stained positively for cytokeratin (A), brachyury (B), and CD24 (C). All sections were counter-
stained with propidium iodide, and images were acquired after adjusting for the negative control (rabbit IgG). Bar = 100 mm.
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measurement (Fig. 5). No tumors developed at the control 
sites (Matrigel alone) in any mouse. Growth kinetics of the 
DVC-4 tumors were much slower than those of the U-CH1 
cells, with no tumors grossly evident in DVC-4–injected 
mice at 4 months after injection. In contrast, U-CH1 cells 
grew tumors very rapidly in NSG mice, as reported pre-
viously, with euthanization times of 15 weeks on average 
(Table 1) as compared with 23 weeks for mice injected 
with the DVC-4 cells. Tumor developed at nearly every site 
injected with U-CH1, whereas gross tumors arose at only 
75% of the sites injected with the DVC-4 cells. Note that 
tumors formed from DVC-4 cells were solid, white, and 
distinct from the surrounding connective tissue.
The U-CH2b cells contributed to the slowest growing 
tumors of all three cell types (Table 1). Tumors developed 
in less than 50% of injected sites as late as 27 weeks after 
injection. While some sites had not yet developed tumors, 
mice injected with U-CH2b cells were still euthanized 
at 27 weeks. It is noteworthy that tumors from U-CH2b 
cells were often gelatinous and stringy and appeared to 
be very confluent with the surrounding connective tissue.
Histological Features of the Xenograft-Derived Tumors
At least some sections of all xenografts stained pos-
itively for both brachyury and CD24, as shown in Table 
2 and Fig. 6. There was little variation in the pattern of 
staining for brachyury among xenografts prepared from all 
three cell types, with approximately half of all examined 
sections showing some evidence of spatial heterogeneity 
in the pattern. A majority of tissue sections were intensely 
positive for brachyury staining, however, with virtually all 
examined sections scored at 2 or 3 for intensity of stain.
In contrast, differences in the pattern and intensity of 
staining for CD24 were noted among xenografts prepared 
Fig. 2. Light microscopy images of cells plated on laminin-rich or gelatin-coated substrates after initial plating and after 6 (p6) 
or 10 (p10) passages (p). Bar = 100 mm.
Fig. 3. Cells were isolated from primary sacral tumor and expanded in culture for comparison with U-CH1 cells in monolayer. 
Cells here are labeled for anti–human brachyury antibody at the initial isolation and plating (A, Day 2 after isolation) and at Pas-
sage 10 (B). The U-CH1 cells are shown for comparison (C). 
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from all 3 cell types (p < 0.05, chi-square test). All sections 
of U-CH1 xenografts stained intensely for CD24 (score of 
3) with a predominantly uniform pattern, while a majority 
of those from U-CH2b xenografts had a low intensity of 
CD24 staining (score of 1) with a predominantly nonuni-
form or heterogeneous staining pattern. Xenografts from 
DVC-4 cells stained for CD24 with a consistent intensity 
of staining and with a highly homogeneous or spatially 
uniform pattern. These observations suggest that the het-
erogeneous staining for CD24, but not brachyury, was 
related to the morphology and growth characteristics of 
the cell-derived chordoma xenograft. Staining with cell-
associated brachyury was common to all tumors and xeno-
grafts, whereas the pattern for CD24 positivity was distinct 
among the three different tumor sources.
Discussion
Animal models are important for studying cancer bi-
ology and assessing the preclinical efficacy of proposed 
therapeutic agents.3 In this study, we documented and 
compared the potential to generate chordoma xenografts 
across 2 cell lines and a primary chordoma cell called 
“DVC-4.” We showed that all 3 sources of chordoma tu-
mor cells were able to form tumors in the immunocom-
promised NSG mouse, as has already been shown for the 
U-CH1 cells.14 Importantly, this report is the first available 
on xenografts generated from U-CH2b cells, for which we 
discovered a relatively low tumorigenicity, with less than 
50% of injected sites developing tumors at the latest time 
point. Our report of this behavior is both novel and sig-
nificant, as prior studies of brachyury positivity and copy 
number aberrations in cultured U-CH2b cells2 were not 
predictive of the potential to generate tumor xenografts in 
vivo, pointing to the need for additional molecular mark-
ers to understand tumor progression. Several prior studies 
have confirmed that morphological appearance, cytoskel-
etal protein staining (vimentin, cytokeratins), and positiv-
ity for S100 and brachyury are essential for characterizing 
a chordoma xenograft;11,12,14,20 however, our results suggest 
that other molecular markers may be needed to distinguish 
tumorigenic potential and growth kinetics.
Brachyury is a transcription factor expressed in em-
bryonic notochord, and prior studies have shown evi-
dence that gene duplication can confer susceptibility to 
chordoma.3,22 Of interest here is our observation that the 
novel primary chordoma cells, DVC-4, had molecular 
staining for brachyury for cells in vitro and partly for tu-
mor xenografts in vivo, which was similar to the pattern 
for U-CH1 cells. A majority of xenografts from U-CH1 
or DVC-4 were intensely positive for brachyury, and both 
xenografts were morphologically solid and intact tissues. 
Moreover, mRNA levels for brachyury in DVC-4 were 
only modestly lower (2-fold) than those for U-CH1. How-
ever, there was no evidence of increased copy numbers 
for the brachyury gene (T) in DVC-4 genomic DNA, as 
compared with the U-CH1 cell line. Nevertheless, tumors 
formed at 75% of all sites injected with DVC-4 cells, as 
TABLE 1: Distribution of tumor xenografts generated in NSG 
mice 
Cells
No. of Mice 
Injected
Mean Time to 
Death (wks)*
Fraction of Injection 
Sites w/ Tumor
U-CH1 8 15.0 ± 0.89 93.75%
U-CH2b 8 27.1 ± 0.89 43.75%
DVC-4 2 23 75%
* Values expressed as means ± standard deviation.
Fig. 4. Primary human chordoma cells isolated from a sacral tumor obtained via resection. At the time of isolation and initial 
plating, expression of CD24 was detected in 49% of all cells via flow cytometry (A, anti–human CD24). CD24 expression contin-
ued to increase in cells with successive passages, as shown by the flow cytometry traces (B) and the graph (C).
Fig. 5. Method for estimating tumor xenograft dimensions in the 
flank after delivery of U-CH1 cells in a Matrigel carrier. Tumor appears 
on the mouse flank (left). Large tumor at time of excision exhibits the 
physaliphorous appearance of the native tumor (right).
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compared with a 95% success rate for U-CH1 cells. These 
observations suggest that DVC-4 may be an important 
cell line for additional studies of chordoma cell biology, 
providing the potential to study different mechanisms, yet 
similar propensities, to drive tumor formation. Additional 
work to more fully characterize a broader panel of mo-
lecular markers for DVC-4 would be important for con-
firming the utility of this novel chordoma cell line.
We did observe that the slow-growing U-CH2b cells, 
which were associated with infrequent tumor generation, 
were also linked to lower staining-intensity scores and 
more heterogeneity in the pattern of staining for CD24. 
The results shown for CD24 positivity suggest that this 
molecular marker may be useful for tracking relations to 
heterogeneity in growth potential and kinetics for chor-
doma. CD24 has already been documented as uniquely 
associated with nucleus pulposus cells8 and more recently 
has been suggested as a molecular marker of progenitor 
cells in the nucleus pulposus.15 The presentation of CD24 
in chordoma emphasizes the link to the nucleus pulposus 
cell lineage and suggests that other molecular markers 
of nucleus pulposus cells may be useful for identifying 
chordoma cells and their relationship to xenograft growth 
potential.
Studies of chordoma xenografts in mouse models re-
main an important step toward understanding relations 
between the in vitro and in vivo biology of these complex 
tumors. Chordoma xenografts are very slow growing and 
challenging to support in vivo, and few reports are avail-
able for direct comparisons across multiple chordoma cell 
lines. Nevertheless, characterizations of xenografts in this 
study were limited by our knowledge of chordoma patho-
biology so that we were only able to study the expression 
of a few molecular markers at the time of mouse termina-
tion. Future studies that make use of the transient expres-
sion of brachyury and other molecular markers would be 
important for tracking tumor growth and cell localization 
in real time in a living model.
TABLE 2: Uniformity and intensity of labeling for tumor xenografts generated in NSG mice* 
Labeling Pattern Labeling Intensity Score†
Marker & Cell Heterogeneous Homogeneous 0 1 2 3
brachyury
  U-CH1 5 10 0 1 3 11
  U-CH2b 10 5 0 1 8 6
  DVC-4 4 2 0 0 0 6
CD24‡
  U-CH1 5 10 0 0 3 12
  U-CH2b 11 4 0 9 5 1
  DVC-4 0 6 0 3 1 2
* Values represent number of tissue sections.
† Score 0–3: no stain to intense cell-associated stain.
‡ Significant differences in scores among cell types for both uniformity and intensity of staining (p < 0.05, Pearson’s chi-square 
test).
Fig. 6. Representative staining of mouse tumor xenografts harvested from NSG mice injected with cells from a primary tumor 
(DVC-4), U-CH1, or U-CH2b. Bar = 100 mm.
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Conclusions
This is the first report of xenografts generated from 
U-CH2b cells in which we discovered a low tumorige-
nicity for U-CH2b as compared with U-CH1, despite 
evidence of chordoma-like characteristics in vitro. For tu-
mors derived from a primary chordoma cell and U-CH1, 
we observed heterogeneous and intense staining for 
CD24, which corresponded to their similar tumorigenic 
potential and growth kinetics. In contrast, U-CH2b tu-
mors stained less intensely for CD24 in a manner that 
may relate to their low tumor growth potential in vivo. 
These results emphasize that many molecular markers, 
including CD24, may be important to distinguish chor-
doma cell types and their tumorigenicity in vivo.
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